Articles tagged "Immunosuppression"

2016 American Transplant Congress
Significant Pharmacokinetic Interaction Between Everolimus and Tacrolimus in De Novo Renal Transplant Recipients.
H.-P. Chang,¹ C.-Y. Lee,² C.-C. Si,¹ M.-K. Tsai,² F.-L. Lin Wu.^1,3
¹Graduate Institute of Clinical Pharmacy, National Taiwan University, College of Medicine, Taipei, Taiwan; ²Surgery, National Taiwan University Hospital, College of Medicine, Taipei, Taiwan.
Studies on the effect of everolimus on tacrolimus pharmacokinetics (PK) were limited and the results were inconsistent. In contrast, studies showed there was little effect…
2016 American Transplant Congress
Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.
J. Clark,¹ T. Sparkes,¹ B. Masters,¹ J. LaMattina,² R. Barth,² M. Moss.¹
¹University of Maryland Medical Center, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD.
Background: Available literature supports basiliximab induction for safe delay of CNI initiation and renal recovery; however there is a paucity of evidence for use in…
2016 American Transplant Congress
Don't Judge a Book by Its Cover: Normal Liver Enzymes After Transplantation Can Be Associated with Pathologies Requiring Intervention.
C. Sanchez,¹ S. Kumer,² S. Olson,¹ R. Gilroy,¹ T. Schmitt,² B. Kane,² R. Taylor.¹
¹Hepatology/Transplant, University of Kansas, Kansas City, KS; ²Surgery, University of Kansas, Kansas City, KS.
Background:Liver biopsies are employed post-transplant generally to evaluate abnormal liver enzymes (LE); however they are not without risk. Whether post-transplant protocol biopsies (PB) serve any…
2016 American Transplant Congress
Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.
D. Taber, V. Phan, A. Wilton, N. Pilch, H. Meadows, J. Fleming, C. Mardis, A. Mardis, C. Bratton, K. Chavin, J. McGillicuddy, S. Nadig, P. Baliga.
MUSC, Charleston, SC.
Objective: The aim of this study was to assess if changing between two different formulations of generic tacrolimus ([tac] Mylan® and Dr. Reddy's Lab®) impacts…
2016 American Transplant Congress
Novel Approaches to Medication Teaching in Solid Organ Transplantation.
D. Tsapepas, N. Jandovitz, S. Dulanya, D. Salerno, S. Hammad, P. Jordan.
NewYork-Presbyterian Hospital, Columbia University, New York.
Technology has become a fundamental part of our daily lives; mobile application (app) technologies enhance a healthcare providers ability to deliver patient-centered care. Solid organ…
2016 American Transplant Congress
The Medication Level Variability Index (MLVI), a Behavioral Biomarker, Predicts Late Allograft Rejection in Pediatric Liver Transplant Recipients – A Prospective Multisite Study.
E. Shemesh,¹ J. Bucuvalas,² R. Anand,³ R. Venick,⁴ E. Alonso,⁵ J. Mitchell,³ R. Annunziato,¹ G. Mazariegos,⁶ B. Shneider.⁷
¹Mount Sinai, New York; ²Children's Hospital, Cincinnati; ³Emmes Corporation, Rockville; ⁴UCLA, Los Angeles; ⁵Lurie Children's Hospital, Chicago; ⁶Children's Hospital, Pittsburgh; ⁷Children's Hospital, Texas.
Objective: The MALT [Medication Adherence in children who had a Liver Transplant (LT), NCT-01154075, R01DK080740 (NIDDK)] multisite study prospectively evaluated a biomarker for erratic medication…
2016 American Transplant Congress
NAD⁺Promotes Allograft Survival Independently of CD4⁺CD25⁺Foxp3⁺ Regulatory T Cells.
A. Elkhal, H. Rodriguez Cetina Biefer, H. Uehara, M. Quante, M. Seyda, J. Schuitenmaker, S. Tullius, A. Elkhal.
Surgery, Transplant Surgery Research Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
CD4+CD25+Foxp3+ regulatory T cells (Tregs) play a central role in the maintenance of immune tolerance and T cell homeostasis. It is known that Tregs promote…
2016 American Transplant Congress
Long-Term Outcomes of ATG versus IL-2 Receptor Antagonist in Low Risk Kidney Transplant Recipients: Donor Factors.
F. Al Ammary, S. Bae, A. Massie, N. Desai, N. Dagher, E. Kraus, A. Wiseman, D. Segev.
JHU, Baltimore; CU, Denver.
Controversy exists regarding the optimal choice of induction therapy in low-risk kidney transplant (KT) recipients. Current guidelines specify induction choices in KT based on recipient…
2016 American Transplant Congress
A Pathway to Belatacept Monotherapy: Alemtuzumab, Belatacept and Rapamycin for Kidney Transplantation.
A. Guasch,¹ H. Xu,² A. Mehta,¹ A. Ghali,¹ S. Mead,¹ H. Gebel,¹ R. Bray,¹ C. Larsen,¹ T. Pearson,¹ A. Kirk.²
¹Emory Transplant Center, Atlanta, GA; ²Duke University, Durham, NC.
Kidney transplantation remains limited by toxicities of calcineurin inhibitors (CNIs) and steroids. Belatacept is a less toxic CNI alternative delivered by monthly intravenous infusion, but…
2016 American Transplant Congress
The Impact of Different Immunosuppressive Protocols on Early and Long Term Outcomes After Kidney and Pancreas Transplantation.
A. Rajab, R. Pelletier, A. El-Hinnawi, E. Elkhammas, G. Bumgardner, M. Henry.
Surgery/Transplant, The Ohio State University Wexner Medical Center, Columbus, OH.
Between January 1990 and December 2014, 800 combined kidney pancreas transplant procedures were performed at The Ohio State University. The immunosuppressive protocols have changed significantly…